Opinion|Videos|December 30, 2024
Administering Bispecifics in the Community vs Academic Centers
Panelists discuss understanding the comparative advantages, decision-making factors, infrastructure requirements, and partnership models for administering bispecific antibodies in community vs academic settings, with particular focus on patient care logistics and referral pathways.
Advertisement
Video content above is prompted by the following
- What are the benefits of administering bispecific antibodies in the community setting compared with tertiary centers?
- What factors might influence the decision to administer these agents at an academic center instead of in a community setting?
- What kind of infrastructure is needed to administer these agents in the community setting that poses key challenges?
- How are you partnering with academic or community centers to support these patients? What is your internal referral pathway?
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Related Articles
- IVIG Therapy Reduced Infections by 67% in Patients With Multiple Myeloma
September 19th 2025
- IMS 2025: Shifting Immunotherapies to Outpatient Care for Multiple Myeloma
September 19th 2025
- IMS 2025: Improving Outcomes with Bispecifics in Multiple Myeloma
September 19th 2025
- IMS 2025: Quadruplet Regimens Enhance Depth of Response in Multiple Myeloma
September 18th 2025
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times - Pharmacy Practice News and Expert Insights
1
ACIP Meeting: COVID-19 Vaccines to be Administered Through Shared Clinical Decision-Making
2
ACIP Meeting: Combined MMRV Vaccine, Hepatitis B Vaccine Restricted for Some Age Groups
3
Intelligent Pharmacy: Leveraging AI and Automation to Enhance Patient Care and Pharmacist Roles
4
FDA Approves Keytruda Qlex Subcutaneous Injection for Adult and Pediatric Patients With Solid Tumors
5